BIVI Research Note — Evidence Before the Headline
BioViespeed fell to $20.06, while negative gross margin and a larger share count leave the recovery thesis dependent on fresh factory evidence.
Biotechnology
BIVI Deep Coverage Review — Analysis as of July 31, 2026
BioViespeed’s lower share price does not repair negative gross margin, weak utilization or dilution risk ahead of the next operating update.